Aims: The present study aims to explore the role of Tanshinone IIA administration on the protective effect of early renal damage in patients with type 2 diabetes.
Methods: 64 patients with type 2 diabetes who have not been suffered from persistent renal complaints accepted to participate. Subjects were randomly allocated in two groups of trial (oral hypoglycemic drugs plus intravenous Tanshinone IIA 1 mg/kg daily for 3 weeks period) and control (oral hypoglycemic drugs). Information on microalbuminuria, serum β2-microglobulin, urine β2-microglobulin and serum cystatin C was collected from subjects. Although significant improvement was not observed between two groups in glycated hemoglobin A1c (HbA1c), the primary outcome parameters were significantly reduced.
Results: At the endpoints of observation for 21 days of Tanshinone IIA infusion, all patients in the trial group obtained reduction of the levels of microalbuminuria (p < 0.05), serum β2-microglobulin (p < 0.05), urine β2-microglobulin (p < 0.01) and serum cystatin C (p < 0.05).
Conclusions: Our results suggest that Tanshinone IIA might have protective effects on early renal damage with Type 2 diabetes and improve renal function. We believe that Tanshinone IIA could be a new evidence-based therapies in diabetic nephropathy.
Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.